MARKET

JAGX

JAGX

Jaguar Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
+0.070
+5.65%
Pre Market: 1.350 +0.04 +3.05% 04:57 05/10 EDT
OPEN
1.230
PREV CLOSE
1.240
HIGH
1.330
LOW
1.230
VOLUME
2.54K
TURNOVER
--
52 WEEK HIGH
4.470
52 WEEK LOW
0.1850
MARKET CAP
179.89M
P/E (TTM)
-0.9659
1D
5D
1M
3M
1Y
5Y
Jaguar Health Stock Is Estimated To Be Significantly Overvalued
GuruFocus News · 5d ago
Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan
Company terminates at-the-market (ATM) financing programSAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") ...
ACCESSWIRE · 04/29 14:08
Jaguar Health announces $10.8 million registered direct offering
Jaguar Health ([[JAGX]] -3.0%) has announced a registered direct offering of ~7.6M shares of common stock for gross proceeds of ~$10.8M.The securities purchase agreement signed with North American institutional investors for the
Seekingalpha · 04/29 13:51
Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
ACCESSWIRE · 04/29 13:00
This Penny Stock Is Creeping Up To A Key Technical Level
Naked Brand Group LTD. (NASDAQ: NAKD) moved higher Friday, likely after shareholders voted for approval of the proposed transaction to divest its Bendon brand brick-and-mortar operations.
Benzinga · 04/25 12:50
Ocugen, Brooklyn ImmunoTherapeutics leads healthcare gainers; Inovio Pharmaceuticals, Protara Therapeutics among major losers
Gainers: Ocugen (OCGN) +24%, Brooklyn ImmunoTherapeutics (BTX) +20%, BioVie (BIVI) +16%, 22nd Century (XXII) +12%, Jaguar Health (JAGX) +7%.Losers: Inovio Pharmaceuticals (INO) -28%, Protara Therapeutics (TARA) -19%, EDAP TMS (EDAP) -13%, Quidel (QDEL) -10...
Seekingalpha · 04/23 15:01
NKLA, SKLZ, OCGN and MVIS among notable premarket gainers
Sypris Solutions (SYPR) +34% on winning contract for deep space program.Silicon Laboratories (SLAB) +16% as Skyworks buys Infrastructure & Automotive business of the Company.LM Funding America (LMFA) +14% on plans to purchase up
Seekingalpha · 04/23 12:22
Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary
Registration link for webcast interview appears belowCompany premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health, Inc.
ACCESSWIRE · 04/19 13:05
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAGX. Analyze the recent business situations of Jaguar Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAGX stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 4.45M
% Owned: 3.24%
Shares Outstanding: 137.32M
TypeInstitutionsShares
Increased
1
1.71K
New
7
2.09M
Decreased
0
0
Sold Out
2
21.30K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Chief Financial Officer/Chief Accounting Officer
Carol Lizak
Executive Vice President/Secretary
Steven King
Senior Vice President
Melissa Yeager
Chief Compliance Officer/General Counsel
Jonathan Wolin
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jiahao Qiu
Independent Director
Jonathan Siegel
No Data
About JAGX
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. The Company's other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.